The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review.

antipsychotic depressive symptoms lurasidone personalized treatment schizophrenia

Journal

Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646

Informations de publication

Date de publication:
28 Feb 2024
Historique:
received: 07 02 2024
revised: 17 02 2024
accepted: 22 02 2024
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 28 3 2024
Statut: epublish

Résumé

Schizophrenia is a severe mental disorder characterized by positive, negative, affective, and cognitive symptoms. Affective symptoms in patients with schizophrenia have traditionally been overlooked or even neglected because they are not considered as fundamental as positive and negative symptoms in the choice of medication. This paper aims to systematically evaluate the efficacy and safety of lurasidone in the treatment of depressive symptoms of schizophrenia. Lurasidone appears to be particularly effective on the depressive symptomatology of schizophrenia while also alleviating the positive and negative symptoms associated with the illness. The efficacy of lurasidone in treating patients with first-episode psychosis who present with predominant depressive symptoms suggests that this medication may be a valuable treatment option not only for established cases of schizophrenia but also for individuals in the early stages of the illness. The good tolerability of lurasidone is an important factor that may positively influence treatment decisions.

Sections du résumé

BACKGROUND BACKGROUND
Schizophrenia is a severe mental disorder characterized by positive, negative, affective, and cognitive symptoms. Affective symptoms in patients with schizophrenia have traditionally been overlooked or even neglected because they are not considered as fundamental as positive and negative symptoms in the choice of medication.
METHODS METHODS
This paper aims to systematically evaluate the efficacy and safety of lurasidone in the treatment of depressive symptoms of schizophrenia.
RESULTS RESULTS
Lurasidone appears to be particularly effective on the depressive symptomatology of schizophrenia while also alleviating the positive and negative symptoms associated with the illness.
CONCLUSIONS CONCLUSIONS
The efficacy of lurasidone in treating patients with first-episode psychosis who present with predominant depressive symptoms suggests that this medication may be a valuable treatment option not only for established cases of schizophrenia but also for individuals in the early stages of the illness. The good tolerability of lurasidone is an important factor that may positively influence treatment decisions.

Identifiants

pubmed: 38539614
pii: brainsci14030225
doi: 10.3390/brainsci14030225
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Angelini Pharma (Italy)
ID : 2024

Auteurs

Andrea Fiorillo (A)

Department of Psychiatry, University of Campania "L. Vanvitelli", 80138 Naples, Italy.

Gaia Sampogna (G)

Department of Psychiatry, University of Campania "L. Vanvitelli", 80138 Naples, Italy.

Umberto Albert (U)

Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy.
Department of Mental Health, Azienda Sanitaria Universitaria Giuliano Isontina-ASUGI, 34127 Trieste, Italy.

Emi Bondi (E)

Department of Mental Health and Addictions, ASST Papa Giovanni XXIII, 24121 Bergamo, Italy.

Serafino De Giorgi (S)

Department of Mental Health, ASL Lecce, 73100 Lecce, Italy.

Andrea Fagiolini (A)

Division of Psychiatry, University of Siena, 53100 Siena, Italy.

Maurizio Pompili (M)

Department of Neurosciences, Mental Health and Sensory Organs, Sant'Andrea Hospital, Sapienza University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy.

Gianluca Serafini (G)

Section of Psychiatry, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, 16131 Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, 16131 Genoa, Italy.

Umberto Volpe (U)

Clinical Psychiatry Unit, Department of Clinical Neurosciences, Università Politecnica delle Marche, 60126 Ancona, Italy.

Antonio Vita (A)

Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.

Classifications MeSH